CY1113763T1 - Κοκκια περιεχοντα ασταθες σε οξυ χημικο προϊον σε μεγαλη ποσοτητα - Google Patents

Κοκκια περιεχοντα ασταθες σε οξυ χημικο προϊον σε μεγαλη ποσοτητα

Info

Publication number
CY1113763T1
CY1113763T1 CY20121101224T CY121101224T CY1113763T1 CY 1113763 T1 CY1113763 T1 CY 1113763T1 CY 20121101224 T CY20121101224 T CY 20121101224T CY 121101224 T CY121101224 T CY 121101224T CY 1113763 T1 CY1113763 T1 CY 1113763T1
Authority
CY
Cyprus
Prior art keywords
chemical product
contain high
high volatility
acid chemical
granules contain
Prior art date
Application number
CY20121101224T
Other languages
English (en)
Inventor
Toshihiro Shimizu
Yoshinori Nakano
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19136997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113763(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of CY1113763T1 publication Critical patent/CY1113763T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Προσδοκάται η παροχή παρασκευασμάτων όπως κάψουλων που περιέχουν ένα φάρμακο ασταθές σε οξύ (συγκεκριμένα, μία ένωση βενζιμιδαζόλης έχουσα αντιελκωτική δράση, κλπ.) σε υψηλή συγκέντρωση που παρασκευάζονται δια της χρήσεως περίπου 12% κατά βάρος ή περισσότερο (βάσει του συνόλου των κοκκίων) χημικού προϊόντος ασταθούς σε οξύ και αναμίξεως ενός αλκαλικού ανόργανου άλατος με αυτό για την παροχή κοκκίων της τάξεως των περίπου 600 μm ή περισσότερο σε μέσο μέγεθος σωματιδίου.
CY20121101224T 2001-10-17 2012-12-14 Κοκκια περιεχοντα ασταθες σε οξυ χημικο προϊον σε μεγαλη ποσοτητα CY1113763T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001319444 2001-10-17
EP02775358A EP1459737B1 (en) 2001-10-17 2002-10-16 Granules containing acid-unstable chemical in large amount

Publications (1)

Publication Number Publication Date
CY1113763T1 true CY1113763T1 (el) 2016-07-27

Family

ID=19136997

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121101224T CY1113763T1 (el) 2001-10-17 2012-12-14 Κοκκια περιεχοντα ασταθες σε οξυ χημικο προϊον σε μεγαλη ποσοτητα
CY20131100774T CY1114668T1 (el) 2001-10-17 2013-09-09 Κοκκια περιεχοντα λανσοπραzολη σε μεγαλη ποσοτητα

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100774T CY1114668T1 (el) 2001-10-17 2013-09-09 Κοκκια περιεχοντα λανσοπραzολη σε μεγαλη ποσοτητα

Country Status (9)

Country Link
US (1) US8105626B2 (el)
EP (2) EP1459737B1 (el)
CN (1) CN100562317C (el)
CA (1) CA2463690C (el)
CY (2) CY1113763T1 (el)
DK (2) DK2258351T3 (el)
ES (2) ES2426723T3 (el)
PT (2) PT2258351E (el)
WO (1) WO2003032953A1 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2534713T3 (es) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Preparaciones sólidas estables
EP1602362B1 (en) * 2003-03-12 2016-09-28 Takeda Pharmaceutical Company Limited Drug composition having active ingredient adhered at high concentration to spherical core
US20070027189A1 (en) * 2003-09-18 2007-02-01 Altana Pharma Ag Use of known active ingredients as radical scavengers
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20070141137A1 (en) * 2004-03-04 2007-06-21 Naoki Nagahara Stable capsule preparation
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
JP5124267B2 (ja) 2005-02-25 2013-01-23 武田薬品工業株式会社 顆粒の製造方法
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US9040564B2 (en) * 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
CN101208090B (zh) * 2005-04-28 2012-03-21 卫材R&D管理有限公司 稳定化的组合物
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
WO2007109104A2 (en) * 2006-03-16 2007-09-27 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
MX2009004475A (es) 2006-10-27 2009-08-12 Univ Missouri Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
EP2098250B1 (en) * 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
CA2702356C (en) * 2007-10-12 2014-02-11 Takeda Pharmaceuticals North America, Inc. Pharmaceutical formulation comprising a proton pump inhibitor for the treatment of gastrointestinal conditions independent of food intake
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
WO2012001705A2 (en) 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
EP2535045A1 (en) * 2011-06-15 2012-12-19 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical composition of lansoprazole
WO2013141827A1 (en) * 2012-03-21 2013-09-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Enteric coated solid pharmaceutical compositions for proton pump inhibitors
US20150209432A1 (en) 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
CN104414994A (zh) * 2013-08-24 2015-03-18 湖北欧立制药有限公司 兰索拉唑肠溶胶囊及其制备工艺
CN104546790A (zh) * 2013-10-15 2015-04-29 悦康药业集团有限公司 一种兰索拉唑肠溶胶囊及其制备方法
CN104173342A (zh) * 2014-07-30 2014-12-03 福州闽海药业有限公司 一种右旋兰索拉唑组合物
CN105769824A (zh) * 2014-12-16 2016-07-20 四川海思科制药有限公司 一种兰索拉唑缓释胶囊及其制备方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CZ2017315A3 (cs) * 2017-06-02 2018-12-12 Zentiva, K.S. Dávkovací jednotka s PPI (inhibitory protonové pumpy)
WO2018229744A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
CN111789808A (zh) * 2019-04-08 2020-10-20 生达化学制药股份有限公司 口服医药组成物及其结构

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE416649B (sv) 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0832625B2 (ja) 1987-01-29 1996-03-29 武田薬品工業株式会社 有核顆粒およびその製造法
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JPH05139964A (ja) 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
ATE192932T1 (de) 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
JP2676319B2 (ja) 1994-02-09 1997-11-12 大洋薬品工業株式会社 塩酸ニカルジピンの徐放剤用製剤およびこれを利用した徐放化製剤
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
JP2762998B2 (ja) 1997-04-25 1998-06-11 武田薬品工業株式会社 医薬固形組成物用安定化剤および安定化方法
JP3677156B2 (ja) * 1997-09-05 2005-07-27 武田薬品工業株式会社 医薬
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
CA2320963A1 (en) * 1998-01-30 1999-08-05 Sepracor, Inc. R-lansoprazole compositions and methods
ATE526022T1 (de) 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
JP4127740B2 (ja) 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定化したベンズイミダゾール系化合物含有組成物
ES2559766T3 (es) 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
DE69942777D1 (de) 1998-07-28 2010-10-28 Takeda Pharmaceutical Leicht zerfallende feste Zubereitung
TW404832B (en) 1999-01-27 2000-09-11 Nang Kuang Pharmaceutical Co L The oral medicine with good stability cotaining the omeprazole or the analogues
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
EP1108425B1 (en) * 1999-12-16 2005-06-08 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles
CN1193024C (zh) 2000-04-28 2005-03-16 武田药品工业株式会社 生产旋光的亚砜衍生物的方法
CA2496044A1 (en) * 2002-08-16 2004-02-26 Themis Laboratories Private Limited A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles

Also Published As

Publication number Publication date
US8105626B2 (en) 2012-01-31
PT2258351E (pt) 2013-07-29
US20050003005A1 (en) 2005-01-06
WO2003032953A1 (fr) 2003-04-24
EP1459737B1 (en) 2012-09-26
CY1114668T1 (el) 2016-10-05
PT1459737E (pt) 2012-11-26
ES2392960T3 (es) 2012-12-17
EP2258351B1 (en) 2013-06-19
EP2258351A3 (en) 2011-10-12
CN100562317C (zh) 2009-11-25
CA2463690C (en) 2011-08-23
ES2426723T3 (es) 2013-10-24
CN1571659A (zh) 2005-01-26
EP1459737A4 (en) 2007-09-26
EP1459737A1 (en) 2004-09-22
DK1459737T3 (da) 2013-01-02
DK2258351T3 (da) 2013-08-26
EP2258351A2 (en) 2010-12-08
CA2463690A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
CY1113763T1 (el) Κοκκια περιεχοντα ασταθες σε οξυ χημικο προϊον σε μεγαλη ποσοτητα
Meyer et al. Kinetics and equilibria of S‐nitrosothiol—thiol exchange between glutathione, cysteine, penicillamines and serum albumin
DK0796082T3 (da) Orale sammensætninger indeholdende stabiliserede tinforbindelser
KR970014565A (ko) 과립형 제초 조성물
BR9814645A (pt) Derivados de amina cìclica e seu uso como medicamentos
NO960949L (no) Tablettert flerdoseenhetsform inneholdende protonpumpeinhibitor
CY1108130T1 (el) Σταθεροποιηση των δραστικων παραγοντων μεσω τυποποιημενης παρασκευης σε μορφη νανοσυσσωματωματος
CY1106420T1 (el) Νανοσωματιδιακα σκευασματα ινσουλινης
CY1107128T1 (el) Φαρμακευτικα σκευασματα αερολυματος
DE602005004810D1 (de) Hautpflegeverfahren gegen alterserscheinungen mit quaternären ammoniumsalzen als wirkstoffe
ATE192333T1 (de) Partikel mit modifizierten physikalisch- chemischen eigenschaften, ihre herstellung und verwendung
DK1628932T3 (da) Hydrofoberende additiv
BR9809865A (pt) Fixador de perfume, perfume e produto base misturados com o mesmo, e, produto perfumado.
ES2530791T3 (es) Formulación de ibandronato de altas dosis
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
WO2004039326A3 (en) Propofol with cysteine
EP1186292A3 (de) Feste Zubereitungen mit einer Multi-Kern Struktur
AU2001262559A1 (en) Sustained release composition comprising an active agent in a plastic carrier and shaped articles made therefrom
ES2080175T3 (es) Estabilizador para una preparacion que contiene 4-etil-2-hidroxiimino-5-nitro-3-hexenamida y metodo de estabilizacion correspondiente.
ATE472321T1 (de) Pantethin enthaltendes teilchenförmiges produkt
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
ATE503464T1 (de) Fliessfähige, pulverförmige alpha-liponsäure(- derivate) enthaltende zusammensetzung
ATE360429T1 (de) Krebsmittel
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
TH49967A (th) สารฟอสเฟต ต้านฟังไจชนิดเตตราไฮโดรฟูแลน